Company Information

CIN
Status
Date of Incorporation
10 October 2017
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
Last Annual Meeting
Paid Up Capital
Authorised Capital

Directors

Shweta Vijayendrakumar Redasani
Shweta Vijayendrakumar Redasani
Director/Designated Partner
over 2 years ago
Anjali Ashok Choudhary
Anjali Ashok Choudhary
Director/Designated Partner
over 4 years ago
Vijayendra Kumar Virendrakumar Redasani
Vijayendra Kumar Virendrakumar Redasani
Director/Designated Partner
over 4 years ago

Past Directors

Suman Manoj Awasthi
Suman Manoj Awasthi
Partner
about 8 years ago
Prashant Ashok Lambe
Prashant Ashok Lambe
Designated Partner
about 8 years ago

Patents

"Liquid Pharmaceutical Compositions Of Melatonin For Oral And Parenteral Administration"

LIQUID PHARMACEUTICAL COMPOSITIONS OF MELATONIN FOR ORAL AND PARENTERAL ADMINISTRATION Abstract The present invention relates to a liquid compositions for the oral and parenteral administration of melatonin in the form of aqueous solutions comprising melatonin and at least one but preferably two ingredients for...

Pharmaceutical Compositions Of Boswellia Serrata

TITLE: PHARMACEUTICAL COMPOSITIONS OF BOSWELLIA SERRATA The invention provides solubilized compositions of Boswellia Serrata alone or with Curcumin containing from 10 – 90 % Boswellia Serrata and from 5 – 35 % of one or more solubilizer. The invention further provides Gastro resistant and / or colon targeted...

Oral Pharmaceutical Compositions Of Methylnaltrexone And Salt Thereof

The present invention relates to solid oral pharmaceutical compositions of methylnaltrexone and its salts. The compositions are free of an ion pairing agent and particularly free of sodium lauryl sulphate. The compositions contain a solid solubilizer and / or a semi-solid low melting solubilizer which enhances solub...

“High Dose Pharmaceutical Composition Containing Dexamethasone And Its Salt”

The invention relates to high dosed Dexamethasone Compositions or highly 5 concentrated compositions of Dexamethasone having from 20 % - 40 % Dexamethasone, more preferably from 25 – 40 % of Dexamethasone. Dexamethasone herein also includes any derivative, salt, hydrate solvate etc. of Dexamethasone. The prefe...

Charges

1 Crore
28 May 2020
Tata Capital Financial Services Limited
31 Lak
30 October 2019
Tata Capital Financial Services Limited
40 Lak
20 March 2023
Tata Capital Financial Services Limited
37 Lak
20 March 2023
Tata Capital Financial Services Limited
0
30 October 2019
Tata Capital Financial Services Limited
0
28 May 2020
Tata Capital Financial Services Limited
0
20 March 2023
Tata Capital Financial Services Limited
0
30 October 2019
Tata Capital Financial Services Limited
0
28 May 2020
Tata Capital Financial Services Limited
0